Objectives: To determine the prevalence of cognitive dysfunction in SLE patients with overt neuropsychiatric manifestations (NPSLE) or without ovent neuropsychiatric manifestation (nSLE) and its association with disease duration, disease activity, previous neuropsychiatric involvement and medications. Methods: A cross-sectional study of 33 SLE patients, 33 rheumatoid arthritis (RA) patients and 32 healthy subjects (age, sex, and education matched) were evaluated using the standardized neuropsychological battery tests recommended by the American College of Rheumatology Ad HOC Committee on neuropsychiatric lupus nomenclature and the Thai Mental State Examination (TMSE). Disease activity was measured by the SLE Activity Measure (SLAM). Current...
OBJECTIVE: Previous studies on cognitive dysfunction evaluated by electrophysiological test in patie...
Computerized batteries have been widely used to investigate cognitive impairment (CI) in patients wi...
Cognitive impairment (CI) has been described in 3-80% of Systemic lupus erythematosus (SLE) patients...
Objective Cognitive dysfunction in SLE is common, but clinical risk factors are poorly understood. T...
Objective: To determine the frequency of cognitive impairment and it associated risk factors in pati...
AbstractIntroductionSystemic lupus erythematosus (SLE) is a chronic autoimmune disease which can cau...
Background: Neuropsychological manifestations are present in 60 of patients with Systemic Lupus Eryt...
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with diverse clinical manifestat...
Background: Cognitive dysfunction was found in 55-80% Neuropsychiatry Systemic Lupus Erythematosus (...
The purpose of the study was to determine the point prevalence of cognitive dysfunction in patients ...
Introduction: Systemic lupus erythematosus (SLE) is characterized by frequent neuropsychiatric invol...
This thesis investigates the relationship between quantitative correlates of diffuse brain damage an...
The prevalence and pattern of cognitive impairment in systemic lupus erythematosus (SLE) patients wi...
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects mostly women of child-beari...
BACKGROUND: Previous research has provided evidence for cognitive dysfunction as a common symptom of...
OBJECTIVE: Previous studies on cognitive dysfunction evaluated by electrophysiological test in patie...
Computerized batteries have been widely used to investigate cognitive impairment (CI) in patients wi...
Cognitive impairment (CI) has been described in 3-80% of Systemic lupus erythematosus (SLE) patients...
Objective Cognitive dysfunction in SLE is common, but clinical risk factors are poorly understood. T...
Objective: To determine the frequency of cognitive impairment and it associated risk factors in pati...
AbstractIntroductionSystemic lupus erythematosus (SLE) is a chronic autoimmune disease which can cau...
Background: Neuropsychological manifestations are present in 60 of patients with Systemic Lupus Eryt...
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with diverse clinical manifestat...
Background: Cognitive dysfunction was found in 55-80% Neuropsychiatry Systemic Lupus Erythematosus (...
The purpose of the study was to determine the point prevalence of cognitive dysfunction in patients ...
Introduction: Systemic lupus erythematosus (SLE) is characterized by frequent neuropsychiatric invol...
This thesis investigates the relationship between quantitative correlates of diffuse brain damage an...
The prevalence and pattern of cognitive impairment in systemic lupus erythematosus (SLE) patients wi...
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects mostly women of child-beari...
BACKGROUND: Previous research has provided evidence for cognitive dysfunction as a common symptom of...
OBJECTIVE: Previous studies on cognitive dysfunction evaluated by electrophysiological test in patie...
Computerized batteries have been widely used to investigate cognitive impairment (CI) in patients wi...
Cognitive impairment (CI) has been described in 3-80% of Systemic lupus erythematosus (SLE) patients...